Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.

Cancer immunology research - 4 Aug 2026

Keller Alana L, Dennis Kady A, Ohlstrom Denis J, Parzych Sarah E, Walker Zachary J, Novak Amanda J, Pham-Danis Catherine, Medha Tanisha N, Rahkola Jeremy T, Boorgula Meher P, Kohler M Eric, Sherbenou Daniel W

Abstract excerpt

Multiple myeloma is a plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cells and bispecific T cell-engaging (TCE) antibodies. To better understand this treatment resistance, we examined multiple myeloma cells that persisted after these treatments and consistently observed CD45 upregulation as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Immunotherapy, Adoptive

Share to Leukocyte Common Antigens

Share to Multiple Myeloma

Share to Receptors, Chimeric Antigen

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 42269145
DOI: 10.1158/2326-6066.CIR-25-1068
PMCID: PMC13557096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.PMID 42269145Read ↗

CARving a Path Forward: Unveiling T Cell Phenotypes Across the Spectrum of Multiple Myeloma Disease Progression to Inform Future Strategies for Overcoming Resistance to CAR T Therapy.Semantic proximity Read ↗

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read ↗

A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stagesSemantic proximity Read ↗

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read ↗

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and ResistanceSemantic proximity Read ↗

Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Single-cell transcriptional analysis of the immune tumour microenvironment during myeloma disease evolutionSemantic proximity Read ↗

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read ↗

Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaSemantic proximity Read ↗

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meetingSemantic proximity Read ↗

Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapySemantic proximity Read ↗

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.